Trastuzumab Deruxtecan

證據等級: L5

預測適應症: 1 個

Trastuzumab Deruxtecan: From HER2-Positive Breast/Gastric Cancer to Drug-Induced Osteoporosis

One-Sentence Summary

Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate (ADC) currently used to treat HER2-positive breast cancer, gastric cancer, and other tumours. The TxGNN model predicts a possible association with drug-induced osteoporosis, but this prediction is currently supported by 0 clinical trials and 0 publications, and the underlying mechanism appears to point in the opposite direction of clinical plausibility.

Quick Overview

Item	Content
Original Indication	HER2-positive breast cancer, gastric cancer, and other tumours (per drug mechanism description; no formal indication record in this dataset)
Predicted New Indication	Drug-induced osteoporosis
TxGNN Prediction Score	99.31% (rank 7027)
Evidence Level	L5
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in structured form. Based on known information in this evidence pack, trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate whose payload, DXd, is a topoisomerase I inhibitor — a cytotoxic chemotherapy agent class. It is clinically used for HER2-positive breast cancer, gastric cancer, and related tumours.

There is no known mechanistic pathway by which this drug would treat osteoporosis. On the contrary, cytotoxic ADCs and their associated cancer treatment regimens (chemotherapy, corticosteroids, ovarian/endocrine suppression) are recognized risk factors that cause bone loss rather than reverse it. The direction of the predicted association therefore runs counter to the drug's known pharmacology.

Given this, the prediction is best interpreted as likely model noise or a reversed/confounded association within the TxGNN knowledge graph, rather than a genuine repurposing signal. The absence of any supporting clinical trials, literature, or MOA documentation further limits confidence in this prediction.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

This drug is not currently marketed in Finland, and no marketing authorizations are on record.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (ADC) with cytotoxic payload — topoisomerase I inhibitor (DXd)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Cytotoxic drug handling precautions apply, given the cytotoxic (topoisomerase I inhibitor) payload

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score, there is zero clinical trial or literature support (Evidence Level L5), and the proposed mechanism runs counter to the drug's known cytotoxic pharmacology — cytotoxic anticancer agents are more plausibly a cause of drug-induced osteoporosis than a treatment for it. This pattern is consistent with model noise rather than a genuine repurposing signal.

To proceed, the following is needed:

Structured mechanism of action (MOA) data from DrugBank or another authoritative source
TFDA/regulatory package insert data (warnings, contraindications) to complete a baseline safety assessment
Independent biological rationale or preclinical evidence explaining any plausible link to bone metabolism before further investment
Continued literature/trial monitoring in case new evidence emerges
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.